Thus, serum POSTN levels in patients with cholangiocarcinoma were significantly increased compared with that in healthy controls, patients with benign liver diseases, and even patients with breast cancer, indicating that serum POSTN levels could be used as a diagnostic biomarker (96). This evidence concerns the gene POSTN and breast carcinoma.